Peptide Hormones

Peptide hormones are signaling molecules composed of amino acid chains (typically 3-200 residues) that are secreted by endocrine glands and transported through the bloodstream to act on distant target tissues. They represent the largest class of hormones in the human body — over 100 peptide hormones have been identified, regulating virtually every physiological process from metabolism and growth to reproduction and stress response.

Unlike steroid hormones (cortisol, estradiol, testosterone), which are derived from cholesterol and can diffuse across cell membranes, peptide hormones are water-soluble and cannot enter cells directly. They bind to cell-surface receptors — predominantly G-protein coupled receptors (GPCRs) and receptor tyrosine kinases — and initiate intracellular signaling cascades.

Endocrine vs. paracrine vs. autocrine signaling

Peptide hormones operate across multiple signaling modes:

• Endocrine — secreted into the bloodstream, acting on distant organs. Insulin from pancreatic beta cells acts on muscle, liver, and adipose tissue throughout the body.
• Paracrine — acting on nearby cells. Somatostatin released in the stomach acts locally on neighboring gastrin-producing cells.
• Autocrine — acting on the cell that produced them. Some growth factors function in autocrine loops in cancer.
• Neurocrine — released from neurons into the bloodstream. Oxytocin and vasopressin are synthesized in hypothalamic neurons but released from the posterior pituitary into systemic circulation.

Major peptide hormone families

Insulin and related peptides

Insulin (51 amino acids, two chains linked by disulfide bonds) is the most clinically important peptide hormone. Secreted by pancreatic beta cells in response to elevated blood glucose, it promotes glucose uptake, glycogen synthesis, and lipogenesis while suppressing gluconeogenesis and lipolysis. Insulin binds the insulin receptor tyrosine kinase, activating PI3K/AKT and RAS/MAPK pathways.

Related peptides include C-peptide (cleaved from proinsulin during processing), amylin (IAPP, co-secreted with insulin), and the insulin-like growth factors (IGF-1, IGF-2).

Growth hormone and its axis

Growth hormone (GH, somatotropin) is a 191-amino-acid peptide secreted by the anterior pituitary in pulsatile fashion, regulated by hypothalamic GHRH (stimulatory) and somatostatin (inhibitory). GH acts directly on tissues and indirectly through hepatic IGF-1 production. The GH/IGF-1 axis controls linear growth, body composition, and tissue repair.

Hypothalamic releasing hormones

The hypothalamus produces small peptide hormones that control anterior pituitary function:

• GnRH (10 aa) — stimulates LH and FSH release, governing reproduction
• CRH (41 aa) — stimulates ACTH release, governing the stress response
• GHRH (44 aa) — stimulates GH release
• TRH (3 aa) — stimulates TSH (and prolactin) release
• Somatostatin (14 or 28 aa) — inhibits GH, TSH, and numerous GI peptides

These hormones are secreted in pulses, and pulsatility is functionally critical. Continuous GnRH administration paradoxically downregulates LH/FSH — this is exploited clinically with GnRH agonists (leuprolide) for prostate cancer and endometriosis.

ACTH and melanocortins

ACTH (39 amino acids) is cleaved from the precursor protein proopiomelanocortin (POMC), which also yields alpha-MSH, beta-endorphin, and other bioactive peptides. ACTH stimulates cortisol production from the adrenal cortex. The melanocortin system (MC1R-MC5R) regulates pigmentation, appetite, inflammation, and sexual function.

Oxytocin and vasopressin

Nine-amino-acid cyclic peptides differing by only two residues, yet with distinct functions. Oxytocin drives uterine contraction, milk ejection, and social bonding. Vasopressin (ADH) regulates water reabsorption in the kidney and vasoconstriction. Both are synthesized in the hypothalamus and released from the posterior pituitary.

Incretin hormones

GLP-1 (30 amino acids) and GIP are secreted by intestinal enteroendocrine cells in response to nutrient ingestion. They potentiate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. GLP-1 receptor agonists (semaglutide, liraglutide) are among the most commercially successful peptide drugs in history.

Why peptide hormones cannot be taken orally

The oral delivery challenge is a defining limitation of peptide pharmacology:

Enzymatic degradation — gastric pepsin, pancreatic trypsin, chymotrypsin, and brush-border peptidases rapidly hydrolyze peptide bonds. Most peptide hormones are fully degraded in the GI tract before reaching systemic circulation.

Poor membrane permeability — peptide hormones are hydrophilic, charged molecules that cannot passively cross the intestinal epithelium. Their molecular weight (typically >1000 Da) exceeds the upper limit for paracellular transport.

First-pass metabolism — even if a peptide survives the GI tract and is absorbed, hepatic peptidases in the portal circulation further reduce bioavailability.

The result: most peptide hormones have oral bioavailability below 1%. This is why insulin, GH, and most peptide therapeutics require injection.

Exceptions: oral GLP-1 formulations

Oral semaglutide (Rybelsus) overcomes these barriers using a permeation enhancer — SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC creates a localized pH increase in the stomach that protects semaglutide from pepsin and promotes transcellular absorption. Even so, oral bioavailability is only about 1% — requiring a much higher dose (14 mg oral vs. 1 mg injectable weekly) and strict fasting conditions. This illustrates both the progress and the persistent difficulty of oral peptide delivery.

Clinical significance

Peptide hormones are the basis of numerous therapeutic classes: insulin for diabetes, GH for growth deficiency, GnRH analogs for reproductive medicine and oncology, oxytocin for labor induction, somatostatin analogs (octreotide) for acromegaly and neuroendocrine tumors, and GLP-1 agonists for diabetes and obesity. Understanding their biology is foundational to understanding peptide therapy.